Despite some progress, the industry is still in a wait-and-see mode regarding the administration, Congress, and FDA.
Gil Roth
Advertisement
Gil Roth is president of the Pharma & Biopharma OutsourcingAssociation, gil.roth@pharma-bio.org.
Articles by Gil Roth
The outlook for the CMO and CDMO industry may be affected by ever-changing politics.
Advertisement
Latest Updated Articles
- Viewpoint: Challenges and Opportunities for CDMOs
February 1st 2017
- CDMOs: New Administration, New Frontier
August 1st 2017
Advertisement
Advertisement
Trending on BioPharm International
1
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
2
Nano24's Inhaled EXO-CD24 Cuts ARDS Mortality in Phase 2b Trial
3
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
4
Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US
5